The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi… changes any severe adverse events (grade 3 or higher) (G3+ SevAE) compared with chemotherapy (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).
It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).
175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate compared with 250 mg/m2 paclitaxel (very low certainty).
175 mg/m2 paclitaxel may leads to lower response rate ‐ platinum‐sensitive compared with 250 mg/m2 paclitaxel (low certainty).
It is very uncertain whether 175 mg/m2 paclitaxel changes response rate ‐ platinum‐resistant compared with 250 mg/m2 paclitaxel (very low certainty).
The review found no eligible studies for this question.
175 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 250 mg/m2 paclitaxel (low certainty).
175 mg/m2 paclitaxel probably leads to lower neurotoxicity compared with 250 mg/m2 paclitaxel (moderate certainty).
175 mg/m2 paclitaxel showed no clear difference in neutropenia compared with 250 mg/m2 paclitaxel (low certainty).
The review found no eligible studies for this question.